Go to:
Logótipo
Você está em: Start > Publications > View > Uveal melanoma: physiopathology and new in situ-specific therapies
Map of Premises
Principal
Publication

Uveal melanoma: physiopathology and new in situ-specific therapies

Title
Uveal melanoma: physiopathology and new in situ-specific therapies
Type
Another Publication in an International Scientific Journal
Year
2019
Authors
Souto, EB
(Author)
Other
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Zielinska, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Luis, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Carbone, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Martins Gomes, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Souto, SB
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Silva, AM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 84
Pages: 15-32
ISSN: 0344-5704
Publisher: Springer Nature
Scientific classification
CORDIS: Health sciences
Other information
Authenticus ID: P-00Q-MAE
Abstract (EN): Uveal melanoma is the most common primary intraocular tumor in adults. It can arise from melanocytes in the anterior (iris) or posterior uveal tract (choroid and ciliary body). Uveal melanoma has a particular molecular pathogenesis, being characterized by specific chromosome alterations and gene mutations (e.g., GNAQ/GNA11; BAP1), which are considered promising targets for molecular therapy. Primary treatment of uveal melanoma includes radiotherapy (brachytherapy and charged-particle therapy), phototherapy (photocoagulation, transpupillary thermal therapy, and photodynamic therapy) and surgery (local resection, enucleation and exenteration). Approximately half of patients with uveal melanoma will, however, develop metastasis, especially in the liver. The treatment of metastatic uveal melanoma includes systemic chemotherapy, immunotherapy and molecular targeted therapy. Liver-directed therapies, such as resection, chemoembolization, immunoembolization, radioembolization, isolated hepatic perfusion and percutaneous hepatic perfusion, are also available to treat metastatic uveal melanoma. Several clinical trials are being developed to study new therapeutic options to treat uveal melanoma, mainly for those with identified liver metastases. The present work discusses the physiopathology and new in situ-specific therapies for the treatment of uveal melanoma.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 18
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

The role of the glutamine transporter ASCT2 in antineoplastic therapy (2021)
Article in International Scientific Journal
Teixeira, E; Silva, C; Martel, F
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma (2014)
Article in International Scientific Journal
Ana S Soares; Vera M Costa; Carmen Diniz; Paula Fresco
Liposomal therapies in oncology: does one size fit all? (2018)
Article in International Scientific Journal
Sousa, I; Rodrigues, F; Prazeres, H; Lima, RT; Soares, P
Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy (2010)
Article in International Scientific Journal
Augusto Nogueira; Raquel Catarino; Ana Coelho; Antonio Araujo; Monica Gomes; Rui Medeiros
Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma (2024)
Article in International Scientific Journal
Sousa, SM; Branco, H; Avan, A; Palmeira, A; Morelli, L; Santos, LL; Giovannetti, E; Helena Vasconcelos, MH; Xavier, CPR
Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-24 at 10:46:01 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book